Background Atrial fibrillation (AF) is a severe epidemiological and public health concern
among the elderly population worldwide, with substantial economic and social burdens …

Background Atrial fibrillation (AF) remains the most common form of cardiac arrhythmia.
Management of AF aims to reduce the risk of stroke, heart failure and premature mortality via …

Background Due to limited access to primary percutaneous coronary intervention for the
management of ST-segment elevation myocardial infarction (STEMI) in low-to-middle …

The current use of economic evidence in the decision-making process in the US is
increasing. Meta-analysis of economic evaluations (MAEE) has gained recognition in recent …

Introduction This meta-analysis was conducted to quantitatively pool the incremental net
benefit (INB) of using direct oral anticoagulants (DOACs) for the prevention of venous …

Abstract Purpose of Review To address the following question: Are vitamin K antagonists
(VKA) obsolete as stroke prevention therapy for patients with atrial fibrillation (AF) and …

Myocardial infarction (MI) is a significant cause of morbidity and mortality in low-and middle-
income countries. Fibrinolytic agents and percutaneous coronary intervention (PCI) are the …

Aims Direct-acting oral anticoagulants (DOACs) have, to a substantial degree, replaced
vitamin K antagonists (VKA) as treatments for stroke prevention in atrial fibrillation (AF) …

Background Landmark clinical trials have expended the indications for the direct oral
anticoagulants (DOACs), but contemporary data on usage and expenditure patterns are …

Objectives Dabigatran has a better safety profile and requires less monitoring, but is costlier
than warfarin. This study evaluated the cost-utility of dabigatran relative to warfarin for …